Amgen (AMGN) Earning Neutral News Coverage, Study Finds

Headlines about Amgen (NASDAQ:AMGN) have trended neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of 0.42 on their scale. InfoTrie also assigned news coverage about the medical research company an news buzz score of 7 out of 10, indicating that recent media coverage is likely to have an impact on the company’s share price in the near term.

Here are some of the news headlines that may have impacted Amgen’s ranking:

A number of research analysts recently issued reports on AMGN shares. Cann reiterated a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Monday, July 30th. Citigroup boosted their target price on shares of Amgen from $200.00 to $204.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. Royal Bank of Canada dropped their target price on shares of Amgen to $182.00 and set a “market perform” rating on the stock in a research report on Wednesday, October 31st. Oppenheimer reiterated a “buy” rating and set a $224.00 target price on shares of Amgen in a research report on Tuesday, August 28th. Finally, Mizuho reiterated a “buy” rating and set a $200.00 target price on shares of Amgen in a research report on Friday, July 27th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $204.55.

AMGN traded down $0.01 during trading on Tuesday, hitting $189.91. 67,111 shares of the company’s stock were exchanged, compared to its average volume of 3,346,933. The company has a current ratio of 3.08, a quick ratio of 2.84 and a debt-to-equity ratio of 2.05. Amgen has a fifty-two week low of $163.31 and a fifty-two week high of $210.19. The company has a market cap of $119.20 billion, a price-to-earnings ratio of 15.10, a PEG ratio of 1.95 and a beta of 1.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, October 30th. The medical research company reported $3.69 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.45 by $0.24. Amgen had a net margin of 9.44% and a return on equity of 54.14%. The firm had revenue of $5.90 billion for the quarter, compared to the consensus estimate of $5.78 billion. During the same quarter in the prior year, the company posted $3.27 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. As a group, equities analysts forecast that Amgen will post 14.21 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 7th. Stockholders of record on Friday, November 16th will be paid a $1.32 dividend. The ex-dividend date is Thursday, November 15th. This represents a $5.28 annualized dividend and a dividend yield of 2.78%. Amgen’s payout ratio is 41.97%.

ILLEGAL ACTIVITY NOTICE: “Amgen (AMGN) Earning Neutral News Coverage, Study Finds” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Further Reading: S&P 500 Index

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.

Leave a Reply